PortalPublikationenProceedings from the National Cancer Institute's Second Inte...

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation

Standard

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. / de Lima, Marcos; Porter, David L; Battiwalla, Minoo; Bishop, Michael R; Giralt, Sergio A; Hardy, Nancy M; Kröger, Nicolaus; Wayne, Alan S; Schmid, Christoph.

in: BIOL BLOOD MARROW TR, Jahrgang 20, Nr. 1, 01.01.2014, S. 4-13.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

de Lima, M, Porter, DL, Battiwalla, M, Bishop, MR, Giralt, SA, Hardy, NM, Kröger, N, Wayne, AS & Schmid, C 2014, 'Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation', BIOL BLOOD MARROW TR, Jg. 20, Nr. 1, S. 4-13. https://doi.org/10.1016/j.bbmt.2013.08.012

APA

de Lima, M., Porter, D. L., Battiwalla, M., Bishop, M. R., Giralt, S. A., Hardy, N. M., Kröger, N., Wayne, A. S., & Schmid, C. (2014). Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. BIOL BLOOD MARROW TR, 20(1), 4-13. https://doi.org/10.1016/j.bbmt.2013.08.012

Vancouver

de Lima M, Porter DL, Battiwalla M, Bishop MR, Giralt SA, Hardy NM et al. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. BIOL BLOOD MARROW TR. 2014 Jan 1;20(1):4-13. https://doi.org/10.1016/j.bbmt.2013.08.012

Bibtex

@article{d24949acec6e40759efff1f43569c890,
title = "Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation",
abstract = "In the Second Annual National Cancer Institute's Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, the Scientific/Educational Session on the Prevention and Treatment of Relapse after Allogeneic Transplantation highlighted progress in developing new therapeutic approaches since the first relapse workshop. Recent insights that might provide a basis for the development of novel, practical clinical trials were emphasized, including utilization of newer agents, optimization of donor lymphocyte infusion (DLI), and investigation of novel cellular therapies. Dr. de Lima discussed pre-emptive and maintenance strategies to prevent relapse after transplantation, for example, recent promising results suggestive of enhanced graft-versus-tumor activity with hypomethylating agents. Dr. Schmid provided an overview of adjunctive strategies to improve cell therapy for relapse, including cytoreduction before DLI, combination of targeted agents with DLI, and considerations in use of second transplantations. Dr. Porter addressed strategies to enhance T cell function, including ex vivo activated T cells and T cell engineering, and immunomodulatory approaches to enhance T cell function in vivo, including exogenous cytokines and modulation of costimulatory pathways.",
keywords = "Antineoplastic Agents, Cell- and Tissue-Based Therapy, Graft vs Host Disease, Graft vs Tumor Effect, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Humans, Lymphocyte Depletion, Myeloablative Agonists, National Cancer Institute (U.S.), Recurrence, Survival Analysis, T-Lymphocytes, Transplantation Conditioning, Transplantation, Homologous, United States",
author = "{de Lima}, Marcos and Porter, {David L} and Minoo Battiwalla and Bishop, {Michael R} and Giralt, {Sergio A} and Hardy, {Nancy M} and Nicolaus Kr{\"o}ger and Wayne, {Alan S} and Christoph Schmid",
note = "Published by Elsevier Inc.",
year = "2014",
month = jan,
day = "1",
doi = "10.1016/j.bbmt.2013.08.012",
language = "English",
volume = "20",
pages = "4--13",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1",

}

RIS

TY - JOUR

T1 - Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation

AU - de Lima, Marcos

AU - Porter, David L

AU - Battiwalla, Minoo

AU - Bishop, Michael R

AU - Giralt, Sergio A

AU - Hardy, Nancy M

AU - Kröger, Nicolaus

AU - Wayne, Alan S

AU - Schmid, Christoph

N1 - Published by Elsevier Inc.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - In the Second Annual National Cancer Institute's Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, the Scientific/Educational Session on the Prevention and Treatment of Relapse after Allogeneic Transplantation highlighted progress in developing new therapeutic approaches since the first relapse workshop. Recent insights that might provide a basis for the development of novel, practical clinical trials were emphasized, including utilization of newer agents, optimization of donor lymphocyte infusion (DLI), and investigation of novel cellular therapies. Dr. de Lima discussed pre-emptive and maintenance strategies to prevent relapse after transplantation, for example, recent promising results suggestive of enhanced graft-versus-tumor activity with hypomethylating agents. Dr. Schmid provided an overview of adjunctive strategies to improve cell therapy for relapse, including cytoreduction before DLI, combination of targeted agents with DLI, and considerations in use of second transplantations. Dr. Porter addressed strategies to enhance T cell function, including ex vivo activated T cells and T cell engineering, and immunomodulatory approaches to enhance T cell function in vivo, including exogenous cytokines and modulation of costimulatory pathways.

AB - In the Second Annual National Cancer Institute's Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, the Scientific/Educational Session on the Prevention and Treatment of Relapse after Allogeneic Transplantation highlighted progress in developing new therapeutic approaches since the first relapse workshop. Recent insights that might provide a basis for the development of novel, practical clinical trials were emphasized, including utilization of newer agents, optimization of donor lymphocyte infusion (DLI), and investigation of novel cellular therapies. Dr. de Lima discussed pre-emptive and maintenance strategies to prevent relapse after transplantation, for example, recent promising results suggestive of enhanced graft-versus-tumor activity with hypomethylating agents. Dr. Schmid provided an overview of adjunctive strategies to improve cell therapy for relapse, including cytoreduction before DLI, combination of targeted agents with DLI, and considerations in use of second transplantations. Dr. Porter addressed strategies to enhance T cell function, including ex vivo activated T cells and T cell engineering, and immunomodulatory approaches to enhance T cell function in vivo, including exogenous cytokines and modulation of costimulatory pathways.

KW - Antineoplastic Agents

KW - Cell- and Tissue-Based Therapy

KW - Graft vs Host Disease

KW - Graft vs Tumor Effect

KW - Hematologic Neoplasms

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Lymphocyte Depletion

KW - Myeloablative Agonists

KW - National Cancer Institute (U.S.)

KW - Recurrence

KW - Survival Analysis

KW - T-Lymphocytes

KW - Transplantation Conditioning

KW - Transplantation, Homologous

KW - United States

U2 - 10.1016/j.bbmt.2013.08.012

DO - 10.1016/j.bbmt.2013.08.012

M3 - SCORING: Journal article

C2 - 24018392

VL - 20

SP - 4

EP - 13

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 1

ER -